FMRP silencing via siRNA lipid nanoparticles to reprogram the tumor microenvironment and enhance anti-PD-1 efficacy in triple-negative breast cancer
Fragile X mental retardation protein (FMRP), encoded by the Fmr1 gene, is notably upregulated in various malignancies, including triple-negative breast cancer, pancreatic ductal adenocarcinoma, and colon carcinoma, and potentially mediates immune evasion through multiple mechanisms. Here a small int...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425006453 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Fragile X mental retardation protein (FMRP), encoded by the Fmr1 gene, is notably upregulated in various malignancies, including triple-negative breast cancer, pancreatic ductal adenocarcinoma, and colon carcinoma, and potentially mediates immune evasion through multiple mechanisms. Here a small interfering RNA (siRNA) targeting Fmr1 is designed for tumor site delivery to suppress FMRP expression and enhance immune activation. Lipid nanoparticles loaded with siFmr1 (LNP@siFmr1) are prepared using a microfluidic-based electrospray method, achieving optimal particle size, encapsulation efficiency, and stability. In an orthotopic breast cancer mouse model, LNP@siFmr1 demonstrates effective passive targeting of tumor sites, leading to significant downregulation of FMRP expression. This suppression coincides with the recruitment and activation of CD8+ T cells and immunostimulatory macrophages, effectively inhibiting tumor growth. Furthermore, the combination with PD-1 antibodies achieves approximately 80 % suppression of tumor growth. These findings provide new insights into tumor-targeted siRNA delivery and immunotherapy strategies involving FMRP targeting and PD-1 antibodies. |
|---|---|
| ISSN: | 2590-0064 |